TITLE

Alexion, Others Show Resilience After Breakouts

AUTHOR(S)
KEN SHREVE
PUB. DATE
December 2014
SOURCE
Investors Business Daily;12/3/2014, pB08
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
Stocks that show resilience and trade tightly after a are worth watching. Why? Because price action like this can often a new entry after an initial breakout.
ACCESSION #
99766506

 

Related Articles

  • Alexion, Valeant Hit New Highs, Pace Top Stocks. SCOTT STODDARD // Investors Business Daily;2/12/2014, pB08 

    Several pharmaceutical stocks hit Tuesday even as many Sector Leaders struggled amid the market's strong performance.

  • CHMP ADOPTS POSITIVE OPINION FOR ALEXION'S SOLIRIS IN EUROPE.  // Worldwide Biotech;Jun2007, Vol. 19 Issue 6, p5 

    The article reports that the Committee for Human Medicinal Products of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for Soliris, a drug from Alexion Pharmaceuticals Inc. The drug is for patients with paroxysmal nocturnal hemoglobinuria (PNH)....

  • New biologic: Soliris.  // Formulary;Apr2007, Vol. 42 Issue 4, p215 

    The article reports on the approval of recombinant monoclonal antibody eculizumab from Alexion Pharmaceuticals Inc. for the treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis. Its efficacy is evaluated in a randomized placebo-controlled 26-week study, and a single-arm 52-week...

  • Alexion Soars On Earnings Report.  // BioWorld Today;7/26/2007, Vol. 18 Issue 144, p3 

    The article reveals the increase in the shares of Cheshire, Connecticut-based Alexion Pharmaceuticals Inc. after it released its second-quarter earnings, which showed a smaller than predicted loss. Alexion reported total revenues of $9.8 million, all from sales of recently launched Soliris, and...

  • Alexion Defies Biotech's Slow Sales Trend; Beats Estimates. Boggs, Jennifer // BioWorld Today;7/22/2011, Vol. 22 Issue 141, p1 

    The article reports on the second quarter earnings of Alexion Pharmaceuticals Inc. in 2011, which prompted the company to increase the sales guidance for its paroxysmal nocturnal hemoglobinuria (PNH) drug Soliris. The price of the stocks of the company rose 9 percent on July 21, 2011 to close at...

  • Alexion Gets FDA Nod For Soliris; First Drug For PNH. Boggs, Jennifer // BioWorld Today;3/19/2007, Vol. 18 Issue 53, p1 

    The article reports that the monoclonal antibody product Soliris from Alexion Pharmaceuticals won U.S. Food and Drug Administration approval in paroxysmal nocturnal hemoglobinuria (PNH), making it the first therapy indicated for the rare genetic disorder. The news boosted the shares of Alexion...

  • Alexion Defies Biotech's Slow Sales Trend; Beats Estimates.  // Bioworld Week;7/25/2011, Vol. 19 Issue 30, p5 

    The article reports on the slow sales trend of drug Soliris (eculizumab) manufactured by Alexion Pharmaceuticals Inc. of Cheshire, Connecticut for the treatment of paroxysmal nocturnal hemoglobinuria.

  • Alexion Pharmaceuticals. Investor's Business Daily // Investors Business Daily;4/13/2015, pA02 

    The article focuses on the approval given to Alexion Pharmaceuticals Inc. (ALXN) which will allow update of the label of its drug Soliris for paroxysmal nocturnal hemoglobinuria to include patients without history of transfusion.

  • TGA approval for Soliris.  // Australian Journal of Pharmacy;Apr2009, Vol. 90 Issue 1067, p39 

    The article reports on the approval of Soliris (eculizumab) by the Therapeutic Goods Administration (TGA) of Australia as treatment for the blood disorder paroxysmal nocturnal haemoglobinuria (PNH).

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics